Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...